Biocon Ltd.

BIOCON

₹359.25

-0.28% (-1.0)

Market Cap

₹48,044 Cr.

P/E

124.79

Key Ratios

Edit Ratio's

Market cap

48,044 Cr

124

Prom Holding

54.45 %

ROE (%)

4.68

ROCE (%)

6.08

Div Yield (%)

0.14

Sales

15,770 Cr

OPM (%)

20.70 %

Debt to Equity

0.84

Edit Ratio's

About

Biocon Limited is an innovation-led global biopharmaceuticals company that manufactures biotec… Read more

Low

291

52W Range

High

406

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

8 Yes

Positive for this company

1 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Other Income

Other income component is making ratios of the company look optically better

Price & Performance

Capex vs ROCE

Company has maintained it roce despite making significant capex
ROE

Asset turnover is responsible for roe increase over last 10 years
Sales Growth

Sales of the company has grown at a good pace
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Debt

Company might have issues servicing its debt
Share price

Share price has increased over last 10 years but more due to rerating
Working Capital

Company has significant working capital which is dragging its roce and roe
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Balance Sheet Strength

Balance sheet is weak and might have solvency issues

Market Share

1.52 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.27 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

4.21 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

1.04 %

(as of Nov 21)

Historic

Blood Related - Market Share

27 %

(as of Mar 19)

Source/Historic

CANMAb - Market Share

0.05 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.16 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.04 %

(as of Apr 20)

Historic

Endocrinology - Market Share

0.01 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

75 %

(as of Mar 19)

Source/Historic

Insugen - Market Share

50 %

(as of Mar 19)

Source/Historic

Orlistat API - Market Share

0.01 %

(as of Nov 21)

Historic

Pain - Market Share

21 %

(as of Mar 19)

Source/Historic

Pegfi Igrastim Syringes - Market Sharee

0.30 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

30 %

(as of Mar 20)

Source/Historic

Trastuzumab - Market Share

0.15 %

(as of Jul 22)

Historic

Vaccines - Market Share

0 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

CANMAb

Insugen

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Sobha Ltd.
Alkyl Amines Chemicals Ltd.
B.L. Kashyap and Sons Ltd.

FAQs on Biocon Ltd. Business

What does Biocon do?

Biocon Limited is a global biopharmaceuticals company focusing on developing and manufacturing innovative biologics, biosimilars, and APIs for chronic conditions. They also have a pipeline of novel assets in immunotherapy.

Who are the competitors of Biocon?

Biocon major competitors are Concord Biotech, Advanced Enzyme, Fermenta Biotech, Glaxosmithkline Phar, Glenmark Pharma, Ipca Laboratories, Ajanta Pharma.
Market Cap of Biocon is ₹48,044 Crs.
While the median market cap of its peers are ₹33,517 Crs.

Is Biocon financially stable compared to its competitors?

Biocon seems to be less financially stable compared to its competitors.
Altman Z score of Biocon is 1.58 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Monopoly Companies

Companies which are dominant in a product, usually having a strong moat.

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Aug	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Investor Presentation	May Aug	Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar Apr Jun Jul Sep Dec	Jan Mar Jun Sep Dec	Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Conference Call	Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Biocon Ltd.

Biocon Biologics Serum Lifesciences collaboration call notes - JST Investments

View the discussion on ValuePickr

Industrial Biotechnology - Insulin Production - NPTEL

How Biocon produces Insulin using rDNA Technology - Bio Science

Biocon - Viatris Takeover Primer - JST Investments

Biocon Biologics - An effort to understand the biosimilar business - Dr Midhun

Biotech to Billions: THINK BIG, NEVER GIVE UP & DISRUPT - G2G Ajay

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Biocon Ltd.

Biocon Ltd.

Key Ratios

About

Timeline

Company Timeline

8 Yes

1 Neutral

8 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Other Income

Price & Performance

Capex vs ROCE

ROE

Sales Growth

Current vs Historic Valuation

Debt

Share price

Working Capital

Margin Stability

ROCE Strength

Balance Sheet Strength

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Operating Profit Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

What does Biocon do?

Who are the competitors of Biocon?

Is Biocon financially stable compared to its competitors?

Biocon Ltd.

Biocon Ltd.

Key Ratios

About

Timeline

Company Timeline

8 Yes

1 Neutral

8 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Other Income

Price & Performance

Capex vs ROCE

ROE

Sales Growth

Current vs Historic Valuation

Debt

Share price

Working Capital

Margin Stability

ROCE Strength

Balance Sheet Strength

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Operating Profit Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

What does Biocon do?

Who are the competitors of Biocon?

Is Biocon financially stable compared to its competitors?

SIGN UP FOR FREE